DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma

Inclusion Criteria:

• Histologically proven renal cell carcinoma

• Age: > 18

• WHO- ECOG Performance Status 0-1

• At least one measurable tumor lesions according to the RECIST criteria.

• Life expectancy more than 3 months

• Written informed consent

Exclusion Criteria:

• Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinomas in situ of the cervix and basal/squamous cell carcinomasof the skin).

• Patients with metastatic disease in the central nervous system (CNS).

• Patients with other significant illness including severe allergy, asthma, anginapectoris or congestive heart failure.

• Patients with acute or chronic infection including HIV.

• Patients who are pregnant or nursing.

• Patients who have received antineoplastic therapy including chemotherapy orimmunotherapy less than 4 weeks before beginning the trial.

• Patients who receive corticosteroids or other immunosuppressive agents.

• Patients with active autoimmune diseases such as lupus erythematosus, rheumatoidarthritis or thyroiditis.